First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
- DOI
- 10.1007/s00432-020-03311-w
- Published
- 2020-07-07
- Container
- J Cancer Res Clin Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00432-020-03311-w,
title = {First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.},
author = {Landre T and Des Guetz G and Chouahnia K and Duchemann B and Assié JB and Chouaid C.},
year = {2020},
journal = {J Cancer Res Clin Oncol},
doi = {10.1007/s00432-020-03311-w},
url = {https://doi.org/10.1007/s00432-020-03311-w}
}RIS
TY - JOUR TI - First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. AU - Landre T AU - Des Guetz G AU - Chouahnia K AU - Duchemann B AU - Assié JB AU - Chouaid C. PY - 2020 JO - J Cancer Res Clin Oncol DO - 10.1007/s00432-020-03311-w UR - https://doi.org/10.1007/s00432-020-03311-w ER -
APA
T, L., G, D. G., K, C., B, D., JB, A., & C., C. (2020). First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-020-03311-w
Source records
- europe-pmc · retrieved 2026-09-27T02:33:58.829Z